Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vibhu Banala"'
Autor:
Mario Mietzsch, J. Kennon Smith, Jennifer C. Yu, Vibhu Banala, Shanan N. Emmanuel, Ariana Jose, Paul Chipman, Nilakshee Bhattacharya, Robert McKenna, Mavis Agbandje-McKenna
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss , Pp 362-373 (2020)
Affinity-based purification of adeno-associated virus (AAV) vectors has replaced density-based methods for vectors used in clinical settings. This method utilizes camelid single-domain antibodies recognizing AAV capsids. These include AVB Sepharose (
Externí odkaz:
https://doaj.org/article/28d7c2f26301459a88a2ed347f353059
Autor:
Richard Morgan, Iain Elliot, Vibhu Banala, Christopher Dy, Briana Harris, Elizabeth Anne Ouellette
Publikováno v:
Journal of Brachial Plexus and Peripheral Nerve Injury, Vol 15, Iss 01, Pp e22-e32 (2020)
Background Brachial plexopathy causes pain and loss of function in the affected extremity. Entrapment of the brachial plexus terminal branches within the surrounding connective tissue, or medial brachial fascial compartment, may manifest in debilitat
Externí odkaz:
https://doaj.org/article/d67ef2035c0045b88cecc4c307212163
Autor:
Nilakshee Bhattacharya, Ariana Jose, Jennifer C. Yu, J. Kennon Smith, Shanan N Emmanuel, Mario Mietzsch, Vibhu Banala, Mavis Agbandje-McKenna, Paul R. Chipman, Robert McKenna
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 19, Iss, Pp 362-373 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Affinity-based purification of adeno-associated virus (AAV) vectors has replaced density-based methods for vectors used in clinical settings. This method utilizes camelid single-domain antibodies recognizing AAV capsids. These include AVB Sepharose (
Publikováno v:
Molecular Therapy. 24:S118
Adeno-associated virus (AAV) is one of the most widely studied viral vector systems for therapeutic gene delivery. This application has already experienced success in several human clinical trials, including the treatment of hemophilia B with an rAAV